
Annual report 2024
added 11-12-2025
Cyclerion Therapeutics Net Debt 2011-2026 | CYCN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Cyclerion Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -51.1 M | -21 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21 M | -51.1 M | -36 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 5.15 | 15.21 % | $ 12.4 B | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Aligos Therapeutics
ALGS
|
-132 M | $ 6.51 | -2.54 % | $ 64.4 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 22.92 | 0.17 % | $ 1.07 B | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 105.19 | 2.21 % | $ 27.2 B | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.0 | -1.32 % | $ 4.94 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-133 M | $ 1.43 | 1.78 % | $ 368 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.24 | -1.85 % | $ 453 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.47 | -0.24 % | $ 3.11 B | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 4.99 | 0.6 % | $ 804 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.58 | -1.25 % | $ 420 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
BioXcel Therapeutics
BTAI
|
56.3 M | $ 1.2 | 4.35 % | $ 14.6 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Cabaletta Bio
CABA
|
-76.6 M | $ 3.31 | -3.92 % | $ 333 M | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
Fennec Pharmaceuticals
FENC
|
17.7 M | $ 6.73 | -0.88 % | $ 192 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | ||
|
Cidara Therapeutics
CDTX
|
-188 M | - | - | $ 1.41 B | ||
|
ChromaDex Corporation
CDXC
|
-62 M | - | -0.88 % | $ 598 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
ContraFect Corporation
CFRX
|
-6.03 M | - | -5.16 % | $ 5.39 M |